KRAS and colorectal carcinoma: Previous studies have demonstrated that serum tumor markers (STMs) and clinicopathological characteristics are both important prognostic factors as well as indicators of the therapeutic effect and recurrence risk in patients with CRC (17–19), while their association with KRAS and MMR status is largely unknown.